Phaseline

Targets › DNMT1

DNMT1 (DNA): drug programs, companies and trials

17 programs from 15 companies in 276 trials: 149 Phase 2, 111 Phase 1, 11 Phase 3, 5 Phase 4; Oncology, Hematology, Neurology; next expected readout Dec 2026.

DNA methyltransferase that methylates CpG residues. Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is essential for epigenetic inheritance. (UniProt, P26358)

Open in Phaseline: the race on DNMT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AbbVieAzacitidine
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 4Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)Jul 2027
National Cancer Institute (NCI)Guadecitabine
DNA methyltransferase (DNMT) inhibitor
DNMT1, DNMT3A, DNMT3BPhase 2Locally Advanced Unresectable Primary Central ChondrosarcomaJan 2027
Taiho OncologyAzacitidine (ASTX030)
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 2Myelodysplastic SyndromesNov 2027
Bristol-Myers SquibbAzacitidine (BMS-986345)
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 2Acute Myeloid Leukemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Angioimmunoblastic T-cell Lymphoma (AITL) …Jul 2028
Virginia Commonwealth UniversityDecitabine-cedazuridine
DNA methyltransferase inhibitor (hypomethylating agent)
DNMT1Phase 2Relapsed / Refractory AMLSep 2031
Fox Chase Cancer CenterGuadecitabine
DNA methyltransferase inhibitor
DNMT1Phase 2Urothelial Carcinoma–
Taiho OncologyDecitabine (ASTX727)
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 1Acute Myeloid LeukemiaDec 2026
University of Southern CaliforniaGuadecitabine
DNMT inhibitor
DNMT1, DNMT3A, DNMT3BPhase 1Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Chronic Myelomonocytic LeukemiaDec 2026
Medical College of WisconsinAzacitadine
DNA methyltransferase inhibitor
DNMT1Phase 1Acute Myeloid Leukemia, in RelapseJan 2027
OtsukaASTX727
Decitabine and cedazuridine combination; decitabine is a DNA methyltransferase inhibitor
DNMT1Phase 1Myelodysplastic SyndromesJun 2027
Memorial Sloan Kettering Cancer CenterGuadecitabine
DNA methyltransferase (DNMT) inhibitor
DNMT1Phase 1Lung CancerJul 2027
The First Affiliated Hospital of Soochow UniversityHypomethylating Agents
DNA methyltransferase inhibitor (azacitidine or decitabine)
DNMT1Phase 1Acute Myeloid Leukemia (AML)Sep 2027
Taiho PharmaceuticalASTX030 (AZA + CED)
DNA methyltransferase inhibitor (azacitidine) combined with cytidine deaminase inhibitor (
DNMT1Phase 1Myelodysplastic Syndrome (MDS)Dec 2027
EpiDestinyDecitabine
DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor
DNMT3A, DNMT1Phase 1Sickle Cell Disease; Multiple Sclerosis; Allogeneic Hematopoietic Stem Cell Transplantation (HSCT); AML (Acute Myeloid Leukemia) …Oct 2028
OtsukaASTX727
Oral decitabine and cedazuridine combination; cedazuridine inhibits cytidine deaminase to
DNMT1Phase 1Lower-risk Myelodysplastic; Malignant Peripheral Nerve Sheath Tumors (MPNST); Non Small Cell Lung Cancer; Neurological Cancer …–
Ajjai Alva, MDGuadecitabine
DNA methyltransferase inhibitor
DNMT1Phase 1Advanced Kidney Cancer–
Royal Marsden NHS Foundation TrustGuadecitabine
DNMT inhibitor; hypomethylating agent
DNMT1Phase 1Non Small Cell Lung Cancer–

Conditions

Acute Myeloid Leukemia (71) Myelodysplastic Syndromes (14) AML (7) Chronic Myelomonocytic Leukemia (6) Acute Myeloid Leukemia (AML) (6) Leukemia, Myeloid, Acute (5) Solid Tumor (5) T-cell Acute Lymphoblastic Leukemia (4) Myeloid Malignancy (4) AML, Adult (4) Sickle Cell Disease (3) Hairy Cell Leukemia (3)

Modalities

small molecule (11), mixed (6)

Companies

Taiho Oncology (2) Otsuka (2) University of Southern California (1) EpiDestiny (1) AbbVie (1) Ajjai Alva, MD (1) National Cancer Institute (NCI) (1) The First Affiliated Hospital of Soochow University (1) Royal Marsden NHS Foundation Trust (1) Bristol-Myers Squibb (1) Taiho Pharmaceutical (1) Medical College of Wisconsin (1) Fox Chase Cancer Center (1) Memorial Sloan Kettering Cancer Center (1) Virginia Commonwealth University (1)

Related targets

DNMT3A (7) DNMT3B (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.